A Phase II Trial of Docetaxel and Erlotinib as First-Line Therapy for Elderly Patients With Androgen-Independent Prostate Cancer
BMC Cancer - United Kingdom
doi 10.1186/1471-2407-7-142
Full Text
Open PDFAbstract
Available in full text
Date
July 27, 2007
Authors
Publisher
Springer Science and Business Media LLC